Literature DB >> 22644023

Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571.

J A Leeds1, M Sachdeva, S Mullin, J Dzink-Fox, M J Lamarche.   

Abstract

LFF571 is a novel semisynthetic thiopeptide and potent inhibitor of Gram-positive bacteria. We report that the antibacterial activity of LFF571 against Clostridium difficile is due to inhibition of translation. Single-step mutants of C. difficile with reduced susceptibility to LFF571 were selected at frequencies of <4.5 × 10(-11) to 1.2 × 10(-9). Sequencing revealed a G260E substitution in the thiopeptide-binding pocket of elongation factor Tu. Importantly, this mutation did not confer cross-resistance to clinically used antimicrobials. These results support the development of LFF571 as a treatment for C. difficile infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644023      PMCID: PMC3421628          DOI: 10.1128/AAC.06354-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Discovery of LFF571: an investigational agent for Clostridium difficile infection.

Authors:  Matthew J LaMarche; Jennifer A Leeds; Adam Amaral; Jason T Brewer; Simon M Bushell; Gejing Deng; Janetta M Dewhurst; Jian Ding; JoAnne Dzink-Fox; Gabriel Gamber; Akash Jain; Kwangho Lee; Lac Lee; Troy Lister; David McKenney; Steve Mullin; Colin Osborne; Deborah Palestrant; Michael A Patane; Elin M Rann; Meena Sachdeva; Jian Shao; Stacey Tiamfook; Anna Trzasko; Lewis Whitehead; Aregahegn Yifru; Donghui Yu; Wanlin Yan; Qingming Zhu
Journal:  J Med Chem       Date:  2012-02-23       Impact factor: 7.446

2.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI).

Authors:  M P Bauer; E J Kuijper; J T van Dissel
Journal:  Clin Microbiol Infect       Date:  2009-12       Impact factor: 8.067

3.  Structural basis of the action of pulvomycin and GE2270 A on elongation factor Tu.

Authors:  Andrea Parmeggiani; Ivo M Krab; Sumio Okamura; Rikke C Nielsen; Jens Nyborg; Poul Nissen
Journal:  Biochemistry       Date:  2006-06-06       Impact factor: 3.162

Review 4.  The chemical basis for the action of the vancomycin group of antibiotics.

Authors:  H R Perkins; M Nieto
Journal:  Ann N Y Acad Sci       Date:  1974-05-10       Impact factor: 5.691

5.  Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.

Authors:  Diane M Citron; Kerin L Tyrrell; C Vreni Merriam; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

6.  Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions.

Authors:  V K Viswanathan; M J Mallozzi; Gayatri Vedantam
Journal:  Gut Microbes       Date:  2010-06-16

7.  A defined growth medium for Clostridium difficile.

Authors:  T Karasawa; S Ikoma; K Yamakawa; S Nakamura
Journal:  Microbiology       Date:  1995-02       Impact factor: 2.777

Review 8.  Treatment of Clostridium difficile infection.

Authors:  Dale N Gerding; Carlene A Muto; Robert C Owens
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

Review 9.  Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.

Authors:  R Nelson
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

10.  Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections.

Authors:  Ian A Critchley; Louis S Green; Casey L Young; James M Bullard; Ron J Evans; Melissa Price; Thale C Jarvis; Joseph W Guiles; Nebojsa Janjic; Urs A Ochsner
Journal:  J Antimicrob Chemother       Date:  2009-03-03       Impact factor: 5.790

View more
  14 in total

1.  Efficacy of LFF571 in a hamster model of Clostridium difficile infection.

Authors:  Anna Trzasko; Jennifer A Leeds; Jens Praestgaard; Matthew J Lamarche; David McKenney
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

Review 2.  Natural products as probes in pharmaceutical research.

Authors:  Esther K Schmitt; D Hoepfner; P Krastel
Journal:  J Ind Microbiol Biotechnol       Date:  2015-10-05       Impact factor: 3.346

3.  Characterization of a novel plasmid-borne thiopeptide gene cluster in Staphylococcus epidermidis strain 115.

Authors:  Philip R Bennallack; Scott R Burt; Michael J Heder; Richard A Robison; Joel S Griffitts
Journal:  J Bacteriol       Date:  2014-10-13       Impact factor: 3.490

Review 4.  Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections.

Authors:  Michael G Dieterle; Krishna Rao; Vincent B Young
Journal:  Ann N Y Acad Sci       Date:  2018-09-21       Impact factor: 5.691

Review 5.  Bacteriocins - a viable alternative to antibiotics?

Authors:  Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Nat Rev Microbiol       Date:  2012-12-24       Impact factor: 60.633

6.  Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.

Authors:  Kathleen Mullane; Christine Lee; Adam Bressler; Martha Buitrago; Karl Weiss; Kristina Dabovic; Jens Praestgaard; Jennifer A Leeds; Johanne Blais; Peter Pertel
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

7.  Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile.

Authors:  Meena Sachdeva; Jennifer A Leeds
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

8.  A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers.

Authors:  Lillian S L Ting; Jens Praestgaard; Nicole Grunenberg; Jenny C Yang; Jennifer A Leeds; Peter Pertel
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

Review 9.  Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.

Authors:  Jennifer A Leeds
Journal:  Cold Spring Harb Perspect Med       Date:  2016-02-01       Impact factor: 6.915

Review 10.  YcaO-Dependent Posttranslational Amide Activation: Biosynthesis, Structure, and Function.

Authors:  Brandon J Burkhart; Christopher J Schwalen; Greg Mann; James H Naismith; Douglas A Mitchell
Journal:  Chem Rev       Date:  2017-03-03       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.